Insider trading surveillance
Insider trading surveillance in Healthcare & Life Sciences sits under active scrutiny from the U.S. Securities and Exchange Commission, which has pursued clinical trial data and M&A-adjacent trading cases with increasing specificity in its enforcement actions. The Financial Industry Regulatory Authority runs parallel surveillance on broker-dealer activity, and both agencies have signaled that biotech volatility around FDA approval decisions creates a recurring pattern they treat as a standing enforcement priority. Compliance officers here are not dealing with abstract risk: they are defending specific event windows.
Watch
- SEC Rule 10b5-1 plan amendments: disclosure requirements now affect executive trading windows around trial readouts
- FINRA surveillance alerts tied to unusual options activity before FDA PDUFA date announcements
- Material nonpublic information policies: gap between clinical operations staff and trading pre-clearance systems
- DOJ parallel criminal referrals in SEC civil insider trading cases involving pharma M&A targets
Recent material activity in Healthcare & Life Sciences
Active monitoring in place across Healthcare & Life Sciences. Material developments related to insider trading surveillance will appear here as they are published.